Candel Therapeutics

(NASDAQ) CADL

Current Price$8.76

Market Cap$642.38M

Since IPO (2021)+25%

5 YearN/A

1 Year+72%

1 Month+70%

Candel Therapeutics Financials at a Glance

Market Cap

$642.38M

Revenue (TTM)

$0.00

Net Income (TTM)

$54.42M

EPS (TTM)

$-0.98

P/E Ratio

-8.97

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$8.76

Volume

104,523

Open

$8.66

Price

$8.76

Volume

104,523

Open

$8.66

Previous Close

$8.76

Daily Range

$7.79 - $9.05

52-Week Range

$4.35 - $9.27

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$8.76

Volume

104,523

Open

$8.66

Previous Close

$8.76

Daily Range

$7.79 - $9.05

52-Week Range

$4.35 - $9.27

CADL News

Candel Reports 88 Percent Q2 Loss Drop

Motley Fool Markets TeamAug 14, 2025

CADL: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Candel Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Paul-Peter Tak, MD, PhD

Website

www.candeltx.com

Headquarters

Needham, MA 02494, US

CADL Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-51%

Return on Capital

-29%

Return on Assets

-27%

Earnings Yield

-11.15%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$642.38M

Shares Outstanding

73.25M

Volume

104.52K

Avg. Volume

1.78M

Financials (TTM)

Gross Profit

$845.00K

Operating Income

$48.27M

EBITDA

$47.42M

Operating Cash Flow

$38.31M

Capital Expenditure

$587.00K

Free Cash Flow

$38.90M

Cash & ST Invst.

$119.73M

Total Debt

$1.90M

Candel Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$149.00K

+39.2%

Gross Margin

0.00%

N/A

Market Cap

$642.38M

N/A

Market Cap/Employee

$16.90M

N/A

Employees

N/A

Net Income

$8.86M

-220.1%

EBITDA

$16.13M

-303.5%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$193.04M

+137.6%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$1.34M

+15.7%

Short Term Debt

$453.00K

-95.4%

Return on Assets

-26.95%

N/A

Return on Invested Capital

-28.95%

N/A

Free Cash Flow

$18.71M

-117.1%

Operating Cash Flow

$18.04M

-109.3%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

CTNMContineum Therapeutics, Inc. Class A Common Stock

CTNMContineum Therapeutics, Inc. Class A Common Stock$13.72-3.45%

KYTXKyverna Therapeutics, Inc.

KYTXKyverna Therapeutics, Inc.$9.49-11.64%

CABACabaletta Bio, Inc.

CABACabaletta Bio, Inc.$3.31-8.31%

EDITEditas Medicine, Inc.

EDITEditas Medicine, Inc.$2.62-8.07%

PRQRProQR Therapeutics N.V.

PRQRProQR Therapeutics N.V.$1.59-3.64%

GNLXGenelux Corporation

GNLXGenelux Corporation$2.92-3.95%

ALDXAldeyra Therapeutics, Inc.

ALDXAldeyra Therapeutics, Inc.$1.68+1.20%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

ONDSOndas

ONDSOndas$10.62-0.05%

INTCIntel

INTCIntel$108.77-0.06%

NOKNokia

NOKNokia$13.95-0.04%

FFord Motor Company

FFord Motor Company$13.40-0.07%

POETPoet Technologies

POETPoet Technologies$15.97-0.22%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$15.06-0.10%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$75.34-0.05%

Questions About CADL

What is the current price of Candel Therapeutics?

Candel Therapeutics is trading at $8.76 per share.

What is the 52-week range for Candel Therapeutics?

Over the past 52 weeks, Candel Therapeutics has traded between $4.35 and $9.27.

How much debt does Candel Therapeutics have?

As of the most recent reporting period, Candel Therapeutics reported total debt of $49.27M.

How much cash does Candel Therapeutics have on hand?

Candel Therapeutics reported $194.83M in cash and cash equivalents in its most recent financial results.

What is Candel Therapeutics’s dividend yield?

Candel Therapeutics does not currently have a dividend yield.

Candel Therapeutics

Candel Therapeutics Financials at a Glance

CADL News

Candel Reports 88 Percent Q2 Loss Drop

CADL: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Candel Therapeutics

CADL Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Candel Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CADL

What is the current price of Candel Therapeutics?

What is the 52-week range for Candel Therapeutics?

How much debt does Candel Therapeutics have?

How much cash does Candel Therapeutics have on hand?

What is Candel Therapeutics’s dividend yield?

Premium Investing Services